Multiple Choice
A pharmaceutical researcher develops a therapy to treat a protein misfolding disorder. Specifically, a mutation in this disorder leads to abnormal protein folding and subsequent intracellular degradation of the protein before it can reach the cell membrane. With the new combination drug therapy, the first drug corrects the processing and trafficking of the protein, enabling it to reach the cell surface membrane. Once the protein has reached the cell surface, its function is enhanced by the second drug. This therapy is most likely to be helpful in which of the following conditions?
A) Alzheimer disease
B) Creutzfeldt-Jakob disease
C) Cystic fibrosis
D) Phenylketonuria
E) Sickle cell anemia
Correct Answer:

Verified
Correct Answer:
Verified
Q45: A 6-year-old girl with chronic anemia requiring
Q46: Non-coding RNA molecules are being studied for
Q47: A 6-year-old girl with chronic anemia requiring
Q48: A 22-year-old male is being evaluated due
Q49: A 19-year-old girl is being tested for
Q51: A 14-year-old boy experiences severe, prolonged bleeding
Q52: A 26-year-old woman is being evaluated for
Q53: A researcher is studying the Fas receptor
Q54: A pharmaceutical researcher performs preclinical testing on
Q55: In an experiment, cultured fibroblasts are mechanically